Department of Vascular Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Expert Rev Proteomics. 2021 Apr;18(4):305-314. doi: 10.1080/14789450.2021.1916473. Epub 2021 May 4.
: Abdominal aortic aneurysm (AAA) is a common, complex, and life-threatening disease. Currently, the pathogenesis of AAA is not well understood. No biomarkers or specific drugs are available for AAA in clinical applications. Proteomics is a powerful tool in biomarker discovery, exploration of pathogenesis, and drug target identification.: We review the application of mass spectrometry-based proteome analysis in AAA patients within the last ten years. Differentially expressed proteins associated with AAA were identified in multiple sample sources, including vascular tissue, intraluminal thrombus, tissue secretome, blood, and cells. Some potential disease biomarkers, pathogenic mechanisms, or therapeutic targets for AAA were discovered using proteome analysis. The challenges and prospects of proteomics applied to AAA are also discussed.: Since most of the previous proteomic studies used relatively small sample sizes, some promising biomarkers need to be validated in multicenter cohorts to accelerate their clinical application. With the rapid development of mass spectrometry technology, modification-specific proteomics and multi-omics research in the future will enhance our understanding of the pathogenesis of AAA and promote biomarker discovery and drug development for clinical translation.
腹主动脉瘤（AAA）是一种常见的、复杂的、危及生命的疾病。目前，AAA 的发病机制尚不清楚。在临床应用中，AAA 没有生物标志物或特定药物。蛋白质组学是发现生物标志物、探索发病机制和确定药物靶点的有力工具。我们回顾了过去十年中基于质谱的蛋白质组分析在 AAA 患者中的应用。在多种样本来源中，包括血管组织、管腔内血栓、组织分泌组、血液和细胞中，鉴定出与 AAA 相关的差异表达蛋白。通过蛋白质组分析发现了一些潜在的疾病生物标志物、发病机制或 AAA 的治疗靶点。还讨论了蛋白质组学在 AAA 中的应用所面临的挑战和前景。由于大多数先前的蛋白质组学研究使用的样本量相对较小，一些有前途的生物标志物需要在多中心队列中进行验证，以加速其临床应用。随着质谱技术的快速发展，未来的修饰特异性蛋白质组学和多组学研究将增强我们对 AAA 发病机制的理解，并促进生物标志物的发现和药物开发，以实现临床转化。
